Dynamic Arginine Methylation of YBX1 Relay Controls Its Phase Separation and Chemoradiotherapy Resistance in Rectal Cancer
Advanced Science · 2025
DOI: 10.1002/advs.202502786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yunxing Shi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China. Hauptthemen laut MEDLINE: Rectal Neoplasms, Arginine, Y-Box-Binding Protein 1, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Program key projects.
Abstract (Originalsprache)
Although neoadjuvant chemoradiotherapy is the standard treatment and significantly improves prognosis of locally advanced rectal cancer, patients may develop primary or secondary therapy resistance. Here, through functional screening, we identify PRMT3 as a key driver of chemoradiotherapy resistance in rectal cancer. PRMT3 induces the arginine methylation of Y‐box binding protein 1 (YBX1), which suppresses YBX1's capacity for phase separation in cytoplasm and is imperative for its nucleus translocation. Subsequently, lysine‐specific demethylase 4A (KDM4A) demethylates YBX1 to unmask the R247 residue and promote its phase separation in the nucleus, which strengthens its ability to transcriptionally regulate expressions of ATP‐binding cassette (ABC) transporters and homologous recombination (HR) repair genes and reinforces chemoradiotherapy resistance. Of particular translational importance, high‐throughput FDA‐approved drugs library screening identifies acipimox as a potent PRMT3 inhibitor and chemoradiotherapy sensitizer. This study offers a tangible prospect for improving therapeutic outcomes in rectal cancer patients in a clinically relevant setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
- Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510030, China.
ORCID-Profile: Liang Kang
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangzhou Municipal Science and Technology Program key projects
Zitieren
APA
Shi, Y., Wan, T., Liu, S., Liu, H., Zeng, Z., Li, W., Liang, Z., Xiong, L., Luo, S., Yuan, Y., Huang, L., & Kang, L. (2025). Dynamic Arginine Methylation of YBX1 Relay Controls Its Phase Separation and Chemoradiotherapy Resistance in Rectal Cancer. Advanced Science. https://doi.org/10.1002/advs.202502786
Vancouver
Shi Y, Wan T, Liu S, Liu H, Zeng Z, Li W, et al. Dynamic Arginine Methylation of YBX1 Relay Controls Its Phase Separation and Chemoradiotherapy Resistance in Rectal Cancer. Advanced Science. 2025. doi:10.1002/advs.202502786
BibTeX
@article{Shi2025,
author = {Shi, Yunxing and Wan, Taixuan and Liu, Shaoru and Liu, Huashan and Zeng, Ziwei and Li, Wenxin and Liang, Zhenxing and Xiong, Li and Luo, Shuanglin and Yuan, Yunfei and Huang, Liang and Kang, Liang},
title = {Dynamic Arginine Methylation of YBX1 Relay Controls Its Phase Separation and Chemoradiotherapy Resistance in Rectal Cancer},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202502786}
}
EUVIMED